10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
BRISTOL MYERS SQUIBB CO | ||
Ticker: BMY Fiscal Year: 2019 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2019 10-K (Filed: Feb 24, 2020) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2019 | Dec 31, 2018 | |
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 12,346 | 6,911 |
| Marketable securities, current | 3,047 | 1,848 |
| Receivables | 7,685 | 5,747 |
| Inventories | 4,293 | 1,195 |
| Other current assets | 1,983 | 2,015 |
| Total Current Assets | 29,354 | 17,716 |
| Property, plant and equipment | 6,252 | 5,027 |
| Goodwill | 22,488 | 6,538 |
| Other intangible assets | 63,969 | 1,091 |
| Deferred Tax Assets, Net of Valuation Allowance, Noncurrent | 510 | 815 |
| Marketable securities, noncurrent | 767 | 1,775 |
| Other Assets, Noncurrent | 6,604 | 2,024 |
| Total Assets | 129,944 | 34,986 |
| LIABILITIES | ||
| Current Liabilities: | ||
| Short-term debt obligations | 3,346 | 1,703 |
| Accounts payable | 2,445 | 1,892 |
| Other current liabilities | 12,513 | 7,059 |
| Total Current Liabilities | 18,304 | 10,654 |
| Deferred Income Tax Liabilities, Net | 6,454 | 19 |
| Long-term debt, excluding current maturities | 43,387 | 5,646 |
| Other Liabilities, Noncurrent | 10,101 | 4,540 |
| Total Liabilities | 78,246 | 20,859 |
| Commitments and contingencies | ||
| EQUITY | ||
| Bristol-Myers Squibb Company Shareholders' Equity: | ||
| Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,568 in 2019 and 3,590 in 2018, liquidation value of $50 per share | 0 | 0 |
| Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2019 and 2.2 billion issued in 2018 | 292 | 221 |
| Capital in excess of par value of stock | 43,709 | 2,081 |
| Accumulated other comprehensive loss | (1,520) | (2,762) |
| Retained earnings | 34,474 | 34,065 |
| Less cost of treasury stock - 672 million common shares in 2019 and 576 million common shares in 2018 | (25,357) | (19,574) |
| Total Bristol-Myers Squibb Company Shareholders' Equity | 51,598 | 14,031 |
| Noncontrolling interest | 100 | 96 |
| Total Equity | 51,698 | 14,127 |
| Total Liabilities and Equity | 129,944 | 34,986 |
| External Links | |
| BRISTOL MYERS SQUIBB CO (BMY) Fiscal Year 2019 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |